Harlan Jones

Dr. Harlan Jones


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2020 in Journal of Racial and Ethnic Health Disparities
Verified
Journal Article
Closed access
PDF file
NPNicole Phillips
Nicole Phillips
IPIn-Woo Park
In-Woo Park
JRJanie R. Robinson
Janie R. Robinson
HJHarlan Jones
Harlan Jones

4 December 2017 in BMC Proceedings
Verified
Journal Article
Open access
PDF file
HJHarlan Jones
Harlan Jones
RMRichard McGee
Richard McGee
AWAnne Marie Weber-Main
Anne Marie Weber-Main
DBDedra S. Buchwald
Dedra S. Buchwald
SMSpero M. Manson
Spero M. Manson
KOKolawole S. Okuyemi
Kolawole S. Okuyemi
Preparing a successful research proposal is one of the most complex skills required of professional scientists, yet this skill is rarely if ever, taught. A major goal of the National Research Mentoring Network (NRMN) in the United States (U.S.) is to support the professional advancement of postdoctoral fellows and junior faculty from diverse populations by offering intensive coaching in the development of grant proposals early in their careers. This article highlights the National Institutes of Health’s (NIH) NRMN initiative to prepare diverse constituencies of early-stage biomedicine scientists for research careers by implementation of an evidence-based nationwide program of comprehensive grant writing and professional development. NRMN delivers four unique but complementary coaching models: the Proposal Preparation Program from the University of Minnesota (UMN); Grantwriters Coaching Groups from Northwestern University (NU); Grantwriting Uncovered: Maximizing Strategies, Help, Opportunities, Experiences from the University of Colorado Anschutz Medical Campus (UC) and Washington State University (WSU); and Steps Towards Academic Research from the University of North Texas Health Science Center (UNTHSC). Because these programs cater to scientists at different career stages, rather than employ a single approach, each is uniquely tailored to test its efficacy at the national level. The first two models prioritize scientists with reasonably well-developed research projects who are ready to write proposals for specific NIH research competitions. The other two models target postdoctoral fellows and early-career faculty who need more extensive guidance in proposal development plans. To achieve scalability, all programs also recruit faculty as Coaches-in-Training to learn approaches and acquire particular group facilitation skills required by each model. These efforts exemplify NRMN’s potential to enhance the career development of diverse trainees on a national scale, building research skills, competitiveness for obtaining faculty positions and capacities that will result in high quality research proposals from a diverse pool of applicants, thereby advancing innovations in science and diversifying the U.S. biomedical workforce.

19 February 2016 in Nanomedicine
Verified
Journal Article
Closed access
RKRutika A Kokate
Rutika A Kokate
PCPankaj Chaudhary
Pankaj Chaudhary
XSXiangle Sun
Xiangle Sun
STSanjay I Thamake
Sanjay I Thamake
SMSayantan Maji
Sayantan Maji
HJHarlan Jones
Harlan Jones
Background: Delivery of PLGA (poly [D, L-lactide-co-glycolide])-based biodegradable nanoparticles (NPs) to antigen presenting cells, particularly dendritic cells, has potential for cancer immunotherapy. Materials & methods: Using a PLGA NP vaccine construct CpG-NP-Tag (CpG-ODN-coated tumor antigen [Tag] encapsulating NP) prepared using solvent evaporation technique we tested the efficacy of ex vivo and in vivo use of this construct as a feasible platform for immune-based therapy. Results: CpG-NP-Tag NPs were avidly endocytosed and localized in the endosomal compartment of bone marrow-derived dendritic cells. Bone marrow-derived dendritic cells exposed to CpG-NP-Tag NPs exhibited an increased maturation (higher CD80/86 expression) and activation status (enhanced IL-12 secretion levels). In vivo results demonstrated attenuation of tumor growth and angiogenesis as well as induction of potent cytotoxic T-lymphocyte responses. Conclusion: Collectively, results validate dendritic cells stimulatory response to C...

31 October 2013 in Cytokine
Verified
Journal Article
Closed access
BKByung-Jin Kim
Byung-Jin Kim
SLSuheung Lee
Suheung Lee
RBRance E. Berg
Rance E. Berg
JSJerry Simecka
Jerry Simecka
HJHarlan Jones
Harlan Jones

29 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
PDPriyanka P. Desai
Priyanka P. Desai
KNKalyani Narra
Kalyani Narra
JJJohanna D. James
Johanna D. James
HJHarlan Jones
Harlan Jones
Amit Kumar TripathiAmit Kumar Tripathi
Amit Kumar Tripathi
Jamboor VishwanathaJamboor Vishwanatha
Jamboor Vishwanatha
Small extracellular vesicles (sEVs), mainly exosomes, are nanovesicles that shed from the membrane as intraluminal vesicles of the multivesicular bodies, serve as vehicles that carry cargo influential in modulating the tumor microenvironment for the multi-step process of cancer metastasis. Annexin A2 (AnxA2), a calcium(Ca2+)-dependent phospholipid-binding protein, is among sEV cargoes. sEV-derived AnxA2 (sEV-AnxA2) protein is involved in the process of metastasis in triple-negative breast cancer (TNBC). The objective of the current study is to determine whether sEV-AnxA2 protein and/or mRNA could be a useful biomarkers to predict the responsiveness of chemotherapy in TNBC. Removal of Immunoglobulin G (IgG) from the serum as well as using the System Bioscience’s ExoQuick Ultra kit resulted in efficient sEV isolation and detection of sEV-AnxA2 protein and mRNA compared to the ultracentrifugation method. The standardized method was applied to the twenty TNBC patient sera for sEV isolation. High levels of sEV-AnxA2 protein and/or mRNA were associated with stage 3 and above in TNBC. Four patients who responded to neoadjuvant chemotherapy had high expression of AnxA2 protein and/or mRNA in sEVs, while other four who did not respond to chemotherapy had low levels of AnxA2 protein and mRNA in sEVs. Our data suggest that the sEV-AnxA2 protein and mRNA could be a combined predictive biomarker for responsiveness to chemotherapy in aggressive TNBC.

11 October 2023 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
IGIsabelle K. Gorham
Isabelle K. Gorham
RBRobert Barber
Robert Barber
HJHarlan Jones
Harlan Jones
NPNicole Phillips
Nicole Phillips
Background: Alterations in mitochondrial DNA (mtDNA) levels have been observed in Alzheimer’s disease and are an area of research that shows promise as a useful biomarker. It is well known that not only are the mitochondria a key player in producing energy for the cell, but they also are known to interact in other important intracellular processes as well as extracellular signaling and communication.Body: This mini review explores how cells use mtDNA as a stress signal, particularly in Alzheimer’s disease. We investigate the measurement of these mtDNA alterations, the mechanisms of mtDNA release, and the immunological effects from the release of these stress signals.Conclusion: Literature indicates a correlation between the release of mtDNA in Alzheimer’s disease and increased immune responses, showing promise as a potential biomarker. However, several questions remain unanswered and there is great potential for future studies in this area.